Coulter Partners successfully completed a search assignment for ArcticZymes Technologies ASA (OSE: AZT) and is pleased to announce the placement of Dr. Frank Mathias as Chair of the Board.

Dr. Mathias is the CEO at Oxford Biomedica, a leading pure-play CDMO within the cell and gene therapy industry. Dr. Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Prior to Rentschler, Dr. Mathias served as CEO of Medigene AG, a publicly listed immuno-oncology company. During his 30-year career, Dr. Mathias has held senior roles at leading global pharmaceutical companies, including Amgen Deutschland GmbH, Servier Deutschland GmbH, and Hoechst AG. In 2019, he was awarded the “EY Entrepreneur of the Year” title in Germany. Dr. Mathias is a pharmacist by training and completed his Doctorate in Pharmacy at Paris VI University.

“We are very pleased to nominate Frank Mathias as our new Chair,” said Jon R. Sandberg, Chairman of the Nomination Committee. “Frank Mathias’ extensive experience and visionary leadership make him the ideal candidate to guide our company into its next phase of development, commercialization and growth.”

Mr. Sandberg continued: “Coulter Partners’ exceptional guidance and professionalism throughout the search process were invaluable. Their deep understanding of our organization's unique needs and culture ensured that we identified the ideal candidate to lead our board and drive our future success."

“I am honored to join ArcticZymes at such a pivotal time,” said Dr. Frank Mathias. “The innovative enzyme solutions developed by ArcticZymes have made significant contributions to advancements in biomanufacturing, enhancing efficiency and quality across the industry. I look forward to contributing to the company’s continued success and collaborative growth.”

----

Dr. Frank Mathias, Chair of the Board at ArcticZymes Technologies

About ArcticZymes Technologies

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in-class enzyme technologies to commercial partners who develop therapeutics, in vitro diagnostics, and molecular research kit products. Our mission is to make our customers' lives easier by unlocking new solutions to enhance quality of life and create a more sustainable healthy world. We provide our customers with cold-adapted enzymes from the arctic environment with unique features including heat lability and activity in challenging environments, as well as, customized engineered novel features which can be easily integrated to fuel their innovations.

For more information, please visit www.arcticzymes.com

About Coulter Partners

We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.

Coulter Partners places new Chair at ArcticZymes Technologies

About ArcticZymes Technologies

About Coulter Partners

Related

Coulter Partners strengthens leadership at IMU Biosciences with placements of Chief Executive Officer and Chief Business Officer

Coulter Partners places new Chief Business Officer at the Cell & Gene Therapy Catapult

Coulter Partners places new Chief Executive Officer at ArcticZymes

Coulter Partners places Chief Development Officer at TargED Biopharmaceuticals